About Index Trending news
Analyze
Top 50 Pricing
Allergan plc

Allergan plc

Work at Allergan plc? Add yourself to this profile

Allergan plc

Allergan is a global pharmaceutical company.

Elsewhere

Alexa global traffic share

Twitter followers

Acquired by
06 Sep 2016
RetroSense
$60,000,000
1
04 Aug 2016
Teva Pharmaceuticals
$40,000,000,000
1
07 Jan 2016
ANTERIOS
1
Locations
HQ
$200,000,000
GEN

Allergan to Acquire Motus Therapeutics Genetic Engineering & Biotechnology News - Biotech from Bench to Business

Health Strategy
Xconomy

Allergan Snags Rhythm’s Diabetes-Related GI Drug for $200M

$1,700,000,000
Allergan , WSJ

Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Po

Health Technology
Xconomy

With Tobira Deal, Allergan Keeps Shopping For "Questionable" Assets

Health Stock markets Strategy
Acquisition
businesswire

Akarna Therapeutics Ltd acquired by Allergan plc | Business Wire

$60,000,000
Xconomy

Allergan Dips Toes into Gene Therapy With $60M Retrosense Buy

$40,000,000,000
NoCamels

Teva Completes $40B Purchase Of Allergan

Strategy
The Motley Fool

Better Buy: Valeant Pharmaceuticals International, Inc. vs. Allergan

The Motley Fool

Why Is Impax Labs Tumbling 11.7% Today

The Motley Fool

3 Top Stocks to Buy for Your Kids in June

The Motley Fool

Carl Icahn Bets Big on Allergan's CEO

Stock markets Strategy
The Motley Fool

8 Top Stocks Billionaires Love

Stock markets
The Motley Fool

Down 27%, Is It Time to Buy Allergan Stock? 3 Things You Need to Know

The Motley Fool

Instant Analysis: Allergan Launches $10B Share Buyback Program

Stock markets Strategy
The Motley Fool

Why Horizon Pharma, NorthStar Realty Finance, and Allergan Jumped Today

Stock markets Health
The Motley Fool

Allergan PLC Shares Shed 19% in April After Being Blindsided by the U.S. Treasury

Stock markets Strategy
Acquisition
FinSMEs

Allergan Acquires Topokine Therapeutics, for $85M

Funding Health
The Motley Fool

Allergan's Credit Rating Appears Safe -- Is Its Stock?

The Motley Fool

Peering Into Allergan's Post-Pfizer Future

Stock markets
The Motley Fool

Allergan's Share Price Makes No Sense -- Until You Consider These Two Things

Stock markets